Printer Friendly

TELIOS ANNOUNCES SBIR GRANT FOR DECORIN

 SAN DIEGO, Nov. 18 /PRNewswire/ -- Telios Pharmaceuticals Inc. (NASDAQ: TLIO) today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant for $500,000 from the National Institutes of Health to help support development of the company's product, Decorin, for the treatment of scarring due to fibrotic diseases of internal organs and injuries of the skin.
 Telios is developing Decorin as a novel treatment for certain diseases associated with excessive extracellular matrix production such as diabetic nephropathy, pulmonary fibrosis, and liver cirrhosis. Scarring caused by the overproduction of matrix can cause dysfunction of such vital organs as the kidney, lungs, liver, and skin as well as the central nervous and cardiovascular systems. Decorin could provide a new approach to treating such disorders by virtue of its ability to counteract the effects of transforming growth factor-beta (TGF-beta), which has been implicated as an important component of the scarring process. The company is conducting preclinical studies of Decorin in models of a variety of fibrotic conditions.
 The SBIR program provides funds to qualified companies in order to accelerate basic research to product development. Telios plans to use the grant for formulation research and preclinical development that is required prior to initiation of clinical studies in humans.
 Telios is a leader in the development of "matrix medicine" -- a new class of therapeutic products that modify or mimic extracellular matrix functions in tissue repair and disease. The company is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ophthalmic wounds, fibrotic diseases (such as certain kidney, liver and lung diseases), cardiovascular diseases, and osteoporosis.
 -0- 11/18/93
 /CONTACT: Audrey D. Keane, director of Corporate Development of Telios Pharmaceuticals, 619-622-2615/
 (TLIO)


CO: Telios Pharmaceuticals Inc. ST: California IN: MTC SU:

JB-EH -- SD004 -- 6098 11/18/93 14:06 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 18, 1993
Words:307
Previous Article:UNIVERSITY OF SAN DIEGO'S LEADING ECONOMIC INDICATORS UP IN SEPTEMBER
Next Article:BOATING INDUSTRY ANTICIPATES HIGHER SALES, MORE JOBS WITH NAFTA'S PASSAGE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters